Life Sciences
As the biopharmaceutical industry shifts its focus toward cell and gene therapies, the manufacturing landscape presents both...
Sample Business Objective #1
Oncology Solutions
Amongst therapeutic areas, oncology unquestionably is the highest unmet need given poor survival, substantial socioeconomic burden, and financial toxicity. Advancements in oncology, with the intent to address these challenges, have resulted in improvement in patient outcomes in recent years. The rapid pace is largely attributed to the emergence of immune therapeutics, innovative modalities, and biosimilars, the increasing shift towards personalization and value-based patient care, and the integration of AI and digital technologies.
This innovation-driven growth has pushed the industry to re-evaluate and further transform the operating models to realize clinical & commercial success, address affordability and refine reimbursement strategies for long-term sustainability.
Our Oncology expert team at FutureBridge can support your oncology drug development and strategic decision-making across stages of development including tumor landscape assessments & competitive benchmarking; scientific, technical, and commercial evaluation, translational feasibility of targets/modalities/platforms, and early indicators of success; indication prioritization based on attractiveness & white space analysis; optimal clinical development strategy & target product profile (TPP) for regulatory success; portfolio optimization; BD&L assessment and forecasting.
Early-stage NSCLC Landscape: How the next decade looks like?
Explore how early-stage NSCLC is shaping up with the entrenchment of new therapies and what new questions have emerged with this paradigm shift.
Learn more in the upcoming webinar on 25 May 2023.
Register here
Current and Evolving Management of Diffuse Large B-Cell Lymphoma Life Sciences
Wondering how to improve your pharma R&D business for hematological malignancies such as NHL, and DLBCL, using evidence-based...
Life Sciences
Wondering how to improve your pharma R&D business for hematological malignancies such as NHL, and DLBCL, using evidence-based...
Disruptive Innovations Shaping the Future of Adoptive Cell Therapies Life Sciences
The therapeutic potential of cell therapies is an established fact, but whether will they be able to overcome challenges posed by Solid Tumors remains a question. With innovative strategies, many types of cell therapies are being developed by Industry and academia...
Life Sciences
The therapeutic potential of cell therapies is an established fact, but whether will they be able to overcome challenges posed by Solid Tumors remains a question. With innovative strategies, many types of cell therapies are being developed by Industry and academia...
Cell Therapies in Solid Tumors: A bright future or a long shot Life Sciences
Surmounting all the challenges, 1st cell therapy approval in solid tumors is anticipated by 2022. The spectacular success of cell therapies observed in heme tumors is not yet realized in solid tumors, however, stepped-up efforts to defeat unyielding tumor...
Life Sciences
Surmounting all the challenges, 1st cell therapy approval in solid tumors is anticipated by 2022. The spectacular success of cell therapies observed in heme tumors is not yet realized in solid tumors, however, stepped-up efforts to defeat unyielding tumor...
Strategic Growth Fields
A convergence of industry transformations and exponential technologies creates a pool of opportunities
Engineered Modalities/Platforms
- Cell & gene therapy
- Antibody Drug Conjugate(ADC)
- Oncolytic viruses/vaccines/Simulatory cytokines
- Targeted protein degrader
Precision Medicine
- Personalization
- Drug precision & Targeted therapy
- Targeted drug delivery
- Theragnostics
Early Detection & Screening
- Clinical algorithms based early detection platform
- Imaging and Radio-pharmaceutical
- Non-invasive biopsies/NSG/Single cell/Others
- Gene Panels
Biomarkers
- Immune
- Genomic
- Phenotypic
- Histologic/Readiologic
Business Objectives
Some examples of diverse business objectives we have worked with our clients
Strategic
- How are companies re-assessing R&D models to enhance productivity, stay competitive and maintain long-term sustainability in oncology?
- Which game changer new innovations/technologies are essential to strengthen and optimize the portfolio in oncology?
- Novel treatment modalities where companies are focusing on
- Procedures and surgery devices that are most attractive for licensing precision technologies
- Digital platforms for better patient care
- How have companies overcome the regulatory & ethical challenges for personalized therapy programs?
- What is the evolution in clinical trial design strategies for early market access?
Tactical
- How are the overall treatment landscape and benchmarks changing for major cancers with personalized therapies, new screening technologies, companion diagnostics, and non-invasive biopsies?
- How clinical trials are being improved to deliver more patient-focused clinical trials in oncology?
- What are the critical considerations to successfully navigate the CMC and regulatory landscape of modalities such as CGTs?
Operational
- What kind of R&D and Innovation setup is required for CAR-T therapy?
- What are the opportunities with next-generation bispecific and antibody drug conjugates?
- What are the major learnings from the energy, sound, and navigation platforms used in aero-defense that can be adopted for increasing precision in medical devices and drug delivery in oncology?
Client's Success Stories
Life Sciences
Situational Assessment and Strategic Intelligence of Cell Therapy Landscape in Solid Tumors Quick overview A leading pharma company wanted to take investment decisions and design a long-term development strategy for CT and therefore wanted to conduct a situational assessment and predict long-term business opportunities in the area of CT in solid tumors....
Quick overview A leading pharma company wanted to take investment decisions and design a long-term development strategy for CT and therefore wanted to conduct a situational assessment and predict long-term business opportunities in the area of CT in solid tumors....
Life Sciences
Prioritization of Assets/MoAs/Targets in SCCHN based on Weak Signals Identification Quick overview The client is a leading player in immuno-oncology and aspires to remain a leader with an increased difference/revenue gap from the followers. To achieve this client wanted to ride on existing and upcoming trends and therefore wanted to determine all the...
Quick overview The client is a leading player in immuno-oncology and aspires to remain a leader with an increased difference/revenue gap from the followers. To achieve this client wanted to ride on existing and upcoming trends and therefore wanted to determine all the...
